144 related articles for article (PubMed ID: 25928216)
1. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).
Jiang X; Lim CZ; Li Z; Lee PL; Yatim SM; Guan P; Li J; Zhou J; Pan J; Chng WJ; Chai CL; Yu Q
PLoS One; 2015; 10(4):e0122983. PubMed ID: 25928216
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
4. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.
Momparler RL; Côté S; Momparler LF; Idaghdour Y
Front Oncol; 2017; 7():19. PubMed ID: 28261562
[TBL] [Abstract][Full Text] [Related]
7. Vitamin C promotes anti-leukemia of DZNep in acute myeloid leukemia.
Long B; Shan Y; Sun Y; Wang T; Li X; Huang K; Zhang W; He Y; Wen R; Li Y; Mai Y; Feng Y; Zhang T; Kang B; Zhang C; Zhu Y; Gu J; Liu J; Zhang X; Pan G
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166357. PubMed ID: 35143932
[TBL] [Abstract][Full Text] [Related]
8. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
[TBL] [Abstract][Full Text] [Related]
9. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
Dinner SN; Giles FJ; Altman JK
Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
Momparler RL; Idaghdour Y; Marquez VE; Momparler LF
Leuk Res; 2012 Aug; 36(8):1049-54. PubMed ID: 22472464
[TBL] [Abstract][Full Text] [Related]
11. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
Heo SK; Noh EK; Kim JY; Jeong YK; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Sci Rep; 2017 Nov; 7(1):15278. PubMed ID: 29127384
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
13. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
Reikvam H; Hoang TT; Bruserud Ø
Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic agents in acute myeloid leukemia.
Stone RM
Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
[TBL] [Abstract][Full Text] [Related]
17. Angiocidin induces differentiation of acute myeloid leukemia cells.
Tuszynski GP; Rothman VL
Exp Mol Pathol; 2013 Dec; 95(3):249-54. PubMed ID: 24036285
[TBL] [Abstract][Full Text] [Related]
18. Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients.
van der Weide K; de Jonge-Peeters S; Huls G; Fehrmann RS; Schuringa JJ; Kuipers F; de Vries EG; Vellenga E
Exp Hematol; 2012 Mar; 40(3):177-186.e6. PubMed ID: 22120639
[TBL] [Abstract][Full Text] [Related]
19. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.
Gao C; Dimitrov T; Yong KJ; Tatetsu H; Jeong HW; Luo HR; Bradner JE; Tenen DG; Chai L
Blood; 2013 Feb; 121(8):1413-21. PubMed ID: 23287862
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia.
Tan KB; Ling LU; Bunte RM; Chng WJ; Chiu GN
J Control Release; 2012 Jun; 160(2):290-8. PubMed ID: 22100388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
